Milestone Pharmaceuticals Inc. (MIST) Stock Analysis & Investment Frameworks

Milestone Pharmaceuticals Inc. (MIST) stock analysis on Invetso. Review Milestone Pharmaceuticals Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

Milestone Pharmaceuticals Inc. Company Overview

Milestone Pharmaceuticals Inc. Key Financial Metrics

About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, specializing in the creation and commercialization of cardiovascular therapeutics. Their flagship product, etripamil, an innovative channel blocker, is currently in advanced clinical development. It is undergoing Phase III trials for the treatment of paroxysmal supraventricular tachycardia (PSVT) in the United States and Canada, while also progressing through Phase II trials for atrial fibrillation and rapid ventricular rate. Furthermore, Milestone Pharmaceuticals has forged a licensing and collaboration alliance with Ji Xing Pharmaceuticals to advance and distribute etripamil for both preventative and therapeutic applications in humans. The company was founded in 2003.

Milestone Pharmaceuticals Inc. Investment Frameworks

Invetso analyzes Milestone Pharmaceuticals Inc. (MIST) across the following frameworks:

Explore More MIST Research